TY - JOUR
T1 - Classifying a distinct form of diabetes in lean individuals with a history of undernutrition
T2 - an international consensus statement
AU - Wadivkar, Pradnyashree
AU - Jebasingh, Felix
AU - Thomas, Nihal
AU - Yajnik, Chittaranjan S
AU - Vaag, Allan Arthur
AU - Kibirige, Davis
AU - Bahendeka, Silver
AU - Bajaj, Mandeep
AU - Boyne, Michael S
AU - Bavuma, Charlotte
AU - Abodo, Jacko
AU - Wild, Sarah
AU - Kolthur-Seetharam, Ullas
AU - Mukhopadhyay, Satinath
AU - Somasundaram, Noel P
AU - Schwarz, Peter
AU - Christensen, Dirk L
AU - Pathan, Faruque
AU - Jones, Angus G
AU - Mathur, Sandeep
AU - Kehlenbrink, Sylvia
AU - Hawkins, Meredith
AU - Vellore Declaration Signatories
N1 - Copyright © 2025 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license. Published by Elsevier Ltd.. All rights reserved.
PY - 2025/10
Y1 - 2025/10
N2 - Since 1955, a form of diabetes in lean, young (BMI <18·5 kg/m2, age <30 years) individuals with a history suggestive of undernutrition from before birth and throughout childhood has been described in the literature. In 1985, WHO formally classified it as malnutrition-related diabetes, but subsequently removed the classification in 1999 over a disagreement as to whether undernutrition was a sufficient risk factor to cause this type of diabetes. Emerging evidence now strongly supports the distinct classification of this unique diabetes phenotype, which is characterised by substantial impairment of pancreatic insulin secretion, with normal hepatic and peripheral insulin sensitivity, an absence of ketoacidosis, and no islet cell autoantibodies. In this consensus statement, we synthesise this evidence to produce a set of common features of the disease, proposed pathogenetic mechanisms, and suggested management and prevention strategies. During a consensus meeting in Vellore, India, in January, 2025, type 5 diabetes was proposed as the nomenclature for this distinct form of diabetes, subsequently formalised at the International Diabetes Federation (IDF) World Diabetes Congress in April, 2025. We call upon the international diabetes community to recognise this distinct form of the disease, and to support the IDF's Type 5 Diabetes Working Group and its goals to promote more research into its phenotype, pathophysiology, and treatment, which will benefit millions of patients worldwide, particularly in low-income and middle-income countries.
AB - Since 1955, a form of diabetes in lean, young (BMI <18·5 kg/m2, age <30 years) individuals with a history suggestive of undernutrition from before birth and throughout childhood has been described in the literature. In 1985, WHO formally classified it as malnutrition-related diabetes, but subsequently removed the classification in 1999 over a disagreement as to whether undernutrition was a sufficient risk factor to cause this type of diabetes. Emerging evidence now strongly supports the distinct classification of this unique diabetes phenotype, which is characterised by substantial impairment of pancreatic insulin secretion, with normal hepatic and peripheral insulin sensitivity, an absence of ketoacidosis, and no islet cell autoantibodies. In this consensus statement, we synthesise this evidence to produce a set of common features of the disease, proposed pathogenetic mechanisms, and suggested management and prevention strategies. During a consensus meeting in Vellore, India, in January, 2025, type 5 diabetes was proposed as the nomenclature for this distinct form of diabetes, subsequently formalised at the International Diabetes Federation (IDF) World Diabetes Congress in April, 2025. We call upon the international diabetes community to recognise this distinct form of the disease, and to support the IDF's Type 5 Diabetes Working Group and its goals to promote more research into its phenotype, pathophysiology, and treatment, which will benefit millions of patients worldwide, particularly in low-income and middle-income countries.
KW - Humans
KW - Malnutrition/complications
KW - Consensus
KW - Diabetes Mellitus/classification
KW - Thinness
UR - http://www.scopus.com/inward/record.url?scp=105016549916&partnerID=8YFLogxK
U2 - 10.1016/S2214-109X(25)00263-3
DO - 10.1016/S2214-109X(25)00263-3
M3 - Review
C2 - 40975084
SN - 2214-109X
VL - 13
SP - e1771-e1776
JO - The Lancet Global Health
JF - The Lancet Global Health
IS - 10
ER -